Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
June 09 2023 - 9:30AM
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY)
(“Clearmind” or “the Company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, will host a virtual
investor conference titled “Psychedelics for Obesity” on Monday,
June 12th, at 10:00 AM EST.
Interested participants are invited to register in advance
by clicking here.
Clearmind recently announced positive pre-clinical results
demonstrating efficacy of its drug candidate MEAI for treating
obesity and metabolic syndrome. The study was led by Professor
Joseph Tam, D.M.D., Ph.D., head of the Obesity and Metabolism
Laboratory and Associate Professor of Pharmacology at the Hebrew
University’s Institute for Drug Research.
Professor Tam will headline the conference discussing the
challenges of obesity and the promising pre-clinical results for
MEAI as a potential treatment.
Dr. Adi Zuloff-Shani, Clearmind’s CEO, will present the
company's achievements and goals.
The conference will also feature Mark Haden, Clearmind's VP of
Business Development, and will be hosted by Shannon Smadella of
Clearmind’s Community Development department.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The company’s intellectual portfolio currently consists of
fourteen patent families. The company intends to seek additional
patents for its compounds whenever warranted and will remain
opportunistic regarding the acquisition of additional intellectual
property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the
Canadian Securities Exchange under the symbol "CMND" and the
Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relations
US: CMND@crescendo-ir.com
invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. Forward-looking statements are not
historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to
differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and
uncertainties affecting the Company, reference is made to the
Company’s reports filed from time to time with the Securities and
Exchange Commission (“SEC”), including, but not limited to, the
risks detailed in the Company’s annual report on Form 20-F filed
with the SEC on February 6, 2023. Forward-looking statements speak
only as of the date the statements are made. Forward-looking
statements speak only as of the date the statements are made. The
Company assumes no obligation to update forward-looking statements
to reflect actual results, subsequent events or circumstances,
changes in assumptions or changes in other factors affecting
forward-looking information except to the extent required by
applicable securities laws. If the Company does update one or more
forward-looking statements, no inference should be drawn that the
Company will make additional updates with respect thereto or with
respect to other forward-looking statements. References and links
to websites have been provided as a convenience, and the
information contained on such websites is not incorporated by
reference into this press release. Clearmind is not responsible for
the contents of third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From May 2024 to Jun 2024
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Jun 2023 to Jun 2024